Pure Bioscience Stock Performance
| PURE Stock | USD 0.05 0.0001 0.20% |
The company holds a Beta of 0.74, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pure Bioscience's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pure Bioscience is expected to be smaller as well. At this point, Pure Bioscience has a negative expected return of -0.42%. Please make sure to check Pure Bioscience's maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if Pure Bioscience performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Pure Bioscience has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 2.5 M | |
| Total Cashflows From Investing Activities | -81 K |
Pure |
Pure Bioscience Relative Risk vs. Return Landscape
If you would invest 7.62 in Pure Bioscience on September 29, 2025 and sell it today you would lose (2.63) from holding Pure Bioscience or give up 34.51% of portfolio value over 90 days. Pure Bioscience is currently does not generate positive expected returns and assumes 6.9332% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of otc stocks are less volatile than Pure, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pure Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pure Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Pure Bioscience, and traders can use it to determine the average amount a Pure Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0607
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PURE |
Based on monthly moving average Pure Bioscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pure Bioscience by adding Pure Bioscience to a well-diversified portfolio.
Pure Bioscience Fundamentals Growth
Pure OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Pure Bioscience, and Pure Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pure OTC Stock performance.
| Return On Equity | -1.29 | |||
| Return On Asset | -0.62 | |||
| Profit Margin | (2.02) % | |||
| Operating Margin | (1.98) % | |||
| Current Valuation | 13.51 M | |||
| Shares Outstanding | 111.36 M | |||
| Price To Earning | 12.49 X | |||
| Price To Book | 3.85 X | |||
| Price To Sales | 8.00 X | |||
| Revenue | 1.85 M | |||
| EBITDA | (3.27 M) | |||
| Cash And Equivalents | 511 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 239 K | |||
| Debt To Equity | 0.09 % | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (2.42 M) | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 4.48 M | |||
| Retained Earnings | (103.22 M) | |||
| Current Asset | 6.14 M | |||
| Current Liabilities | 2.54 M | |||
About Pure Bioscience Performance
By analyzing Pure Bioscience's fundamental ratios, stakeholders can gain valuable insights into Pure Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pure Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pure Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. PURE BIOSCIENCE operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 10 people.Things to note about Pure Bioscience performance evaluation
Checking the ongoing alerts about Pure Bioscience for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Pure Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pure Bioscience generated a negative expected return over the last 90 days | |
| Pure Bioscience has high historical volatility and very poor performance | |
| Pure Bioscience has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 1.85 M. Net Loss for the year was (3.49 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Pure Bioscience currently holds about 511 K in cash with (2.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 41.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Pure Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pure Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Pure Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pure Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pure Bioscience's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Pure Bioscience's otc stock. These opinions can provide insight into Pure Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pure OTC Stock analysis
When running Pure Bioscience's price analysis, check to measure Pure Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pure Bioscience is operating at the current time. Most of Pure Bioscience's value examination focuses on studying past and present price action to predict the probability of Pure Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pure Bioscience's price. Additionally, you may evaluate how the addition of Pure Bioscience to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |